Lyra Therapeutics, Inc. financial data

Symbol
LYRA on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
480 Arsenal Way, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
480 Biomedical, Inc. (to 11/28/2016), Arsenal Vascular, Inc. (to 11/8/2011), Arsenal Medical, Inc. (to 8/12/2010), WMR Biomedical Inc (to 2/27/2009)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 439 % -33.5%
Debt-to-equity 109 % +199%
Return On Equity -179 % -138%
Return On Assets -85.4 % -55.5%
Operating Margin -6.89K % -49.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.5M shares +24.5%
Common Stock, Shares, Outstanding 65.5M shares +32.1%
Entity Public Float 143B USD +39.1%
Common Stock, Value, Issued 65K USD +30%
Weighted Average Number of Shares Outstanding, Basic 65.5M shares +14.9%
Weighted Average Number of Shares Outstanding, Diluted 65.5M shares +14.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.47M USD +3.37%
Research and Development Expense 49.7M USD +9.86%
General and Administrative Expense 19.2M USD +0.76%
Operating Income (Loss) -101M USD -54.1%
Nonoperating Income (Expense) 3.86M USD -5.84%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -97.6M USD -58.1%
Income Tax Expense (Benefit) 50K USD -56.3%
Net Income (Loss) Attributable to Parent -97.6M USD -58.1%
Earnings Per Share, Basic -1.46 USD/shares -25.9%
Earnings Per Share, Diluted -1.46 USD/shares -25.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.8M USD -4.23%
Assets, Current 54.4M USD -48.1%
Property, Plant and Equipment, Net 1.61M USD +122%
Operating Lease, Right-of-Use Asset 20.7M USD +241%
Other Assets, Noncurrent 683K USD -82.3%
Assets 78.8M USD -34.7%
Accounts Payable, Current 2.29M USD -54.7%
Employee-related Liabilities, Current 4.67M USD +57%
Liabilities, Current 15M USD -22.3%
Operating Lease, Liability, Noncurrent 31.3M USD +541%
Liabilities 58.1M USD +60%
Accumulated Other Comprehensive Income (Loss), Net of Tax 20K USD
Retained Earnings (Accumulated Deficit) -394M USD -33%
Stockholders' Equity Attributable to Parent 20.6M USD -75.5%
Liabilities and Equity 78.8M USD -34.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.5M USD -41.7%
Net Cash Provided by (Used in) Financing Activities 8.64M USD +116%
Net Cash Provided by (Used in) Investing Activities 7.86M USD +47.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 65.5M shares +32.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.95M USD +43.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.8M USD -1.72%
Deferred Tax Assets, Valuation Allowance 60M USD +48%
Deferred Tax Assets, Gross 67.3M USD +63.9%
Operating Lease, Liability 35.3M USD +462%
Depreciation 136K USD -52.1%
Payments to Acquire Property, Plant, and Equipment 2.15M USD +4676%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -97.6M USD -58%
Lessee, Operating Lease, Liability, to be Paid 44.5M USD +496%
Property, Plant and Equipment, Gross 5.74M USD
Operating Lease, Liability, Current 4M USD +185%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.49M USD +225%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.12M USD +216%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -32.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.13M USD +682%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.13M USD +129%
Deferred Tax Assets, Operating Loss Carryforwards 30M USD +19.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.51M USD +496%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.39M USD +1166%
Share-based Payment Arrangement, Expense 6.26M USD +1.57%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%